Suppression of human epidermal growth factor receptor 2 via interference increases the chemosensitivity of ovarian carcinoma

Song,Xiaoping; Sun,Kailv; Hu,Jianming; Zhou,Jianghu

doi:10.3892/ol.2016.4341

Suppression of human epidermal growth factor receptor 2 via interference increases the chemosensitivity of ovarian carcinoma

Authors:
- Xiaoping Song
- Kailv Sun
- Jianming Hu
- Jianghu Zhou
View Affiliations

Affiliations: Division of Gynecology and Obstetrics, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China, Division of General Surgery, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China
Published online on: March 16, 2016 https://doi.org/10.3892/ol.2016.4341
Pages: 3028-3032
Copyright: © Song et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The function of human epidermal growth factor receptor 2 (HER2) in the chemosensitivity of ovarian carcinoma has not been fully investigated, therefore, the present study aimed to analyze the potential role of HER2 in ovarian carcinoma chemosensitivity in further detail. SKOV3 cells were transfected with lentiviral‑mediated HER2‑small hairpin RNA (shRNA) molecules to establish the stable expression of HER2‑shRNA in the SKOV3 cell line (knockdown cells; KD) and negative control cell line (NC). The untransfected SKOV3 cell line served as the blank control (CON) group. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and western blot analysis were used to detect the expression of HER2 in the three different cell types, which were subsequently examined for growth inhibition using a cell counting kit‑8 assay. The CON and KD cell strains were utilized to establish xenograft models in nude mice, primarily to detect the expression of the HER2 protein, and additionally to observe tumor size changes under the treatment of cisplatin (DDP) chemotherapy. RT‑qPCR and western blot analysis demonstrated a significant decrease in the levels of HER2 mRNA and protein in the KD cells. The suppression of HER2 expression resulted in an increase of chemotherapy sensitivity in the SKOV3 cells. HER2 protein expression decreased significantly following transduction with specific HER2‑shRNA. Additionally, growth slowed significantly under treatment with DDP in ovarian cancer transplantation tumors. In conclusion, lentivirus‑mediated HER2‑shRNA effectively inhibits the expression of the HER2 gene, and increases the chemosensitivity to DDP in ovarian carcinoma.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Salani R, Santillan A, Zahurak ML, et al: Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: Analysis of prognostic factors and survival outcome. Cancer. 109:685–691. 2007. View Article : Google Scholar : PubMed/NCBI
3	Helm CW: Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer. Surg Oncol Clin N Am. 21:645–663. 2012. View Article : Google Scholar : PubMed/NCBI
4	Lu YM, Rong ML, Shang C, et al: Suppression of HER-2 via siRNA promotes apoptosis and decreases metastatic potential of SKOV3 human ovarian carcinoma cells. Oncol Rep. 29:1133–1139. 2013.PubMed/NCBI
5	Baselga J and Arteaga CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 23:2445–2459. 2005. View Article : Google Scholar : PubMed/NCBI
6	Camilleri-Broët S, Hardy-Bessard AC, Le Tourneau A, Paraiso D, Levrel O, Leduc B, Bain S, Orfeuvre H, Audouin J and Pujade-Lauraine E: GINECO group: HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: A multicenter study of the GINECO group. Ann Oncol. 15:104–112. 2004. View Article : Google Scholar : PubMed/NCBI
7	Lanitis E, Dangaj D, Hagemann IS, et al: Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. PLoS One. 7:e498292012. View Article : Google Scholar : PubMed/NCBI
8	Neve RM, Lane HA and Hynes NE: The role of overexpressed HER2 in transformation. Ann Oncol. 12(Suppl 1): S9–S13. 2001. View Article : Google Scholar : PubMed/NCBI
9	Tai W, Mahato R and Cheng K: The role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 146:264–275. 2010. View Article : Google Scholar : PubMed/NCBI
10	Yu D and Hung MC: Role of erbB2 in breast cancer chemosensitivity. BioEssays. 22:673–680. 2000. View Article : Google Scholar : PubMed/NCBI
11	Berchuck A, Kamel A, Whitaker R, et al: Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50:4087–4091. 1990.PubMed/NCBI
12	Tan DS, Ang JE and Kaye SB: Ovarian cancer: Can we reverse drug resistance? Adv Exp Med Biol. 622:153–167. 2008. View Article : Google Scholar : PubMed/NCBI
13	Fire A, Xu S, Montgomery MK, et al: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 391:806–811. 1998. View Article : Google Scholar : PubMed/NCBI
14	Draz MS, Fang BA, Zhang P, et al: Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections. Theranostics. 4:872–892. 2014. View Article : Google Scholar : PubMed/NCBI
15	Meister G and Tuschl T: Mechanisms of gene silencing by double-stranded RNA. Nature. 431:343–349. 2004. View Article : Google Scholar : PubMed/NCBI
16	Brodersen P, Sakvarelidze-Achard L, Bruun-Rasmussen M, et al: Widespread translational inhibition by plant miRNAs and siRNAs. Science. 320:1185–1190. 2008. View Article : Google Scholar : PubMed/NCBI
17	Tuschl T: Expanding small RNA interference. Nat Biotechnol. 20:446–448. 2002. View Article : Google Scholar : PubMed/NCBI
18	Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL and Montz FJ: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol. 20:1248–1259. 2002. View Article : Google Scholar : PubMed/NCBI
19	Ali AY, Farrand L, Kim JY, et al: Molecular determinants of ovarian cancer chemoresistance: New insights into an old conundrum. Ann N Y Acad Sci. 1271:58–67. 2012. View Article : Google Scholar : PubMed/NCBI
20	Takehana T, Kunitomo K, Suzuki S, et al: Expression of epidermal growth factor receptor in gastric carcinomas. Clin Gastroenterol Hepatol. 1:438–445. 2003. View Article : Google Scholar : PubMed/NCBI
21	Yang G, Cai KQ, Thompson-Lanza JA, Bast RC Jr and Liu J: Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem. 279:4339–4345. 2004. View Article : Google Scholar : PubMed/NCBI
22	Roh H, Pippin J and Drebin JA: Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu. Cancer Res. 60:560–565. 2000.PubMed/NCBI
23	Dullaers M, Van Meirvenne S, Heirman C, et al: Induction of effective antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther. 13:630–640. 2005. View Article : Google Scholar